Untreated non-small cell lung cancer affects the brain
What is Non-small cell lung cancer (NSCLC)?
NSCLC is the most common type of lung cancer, accounting for 80–85% of cases. It grows uncontrollably when lung cells misbehave, developing more slowly than small-cell lung cancer but frequently spreading before symptoms appear. Treatment outcomes improve considerably with early discovery.
Key NSCLC Facts
- It accounts for most lung cancer cases worldwide.
- Growth Pattern: Slower than small-cell lung cancer, but metastasizes before symptoms appear.
- Compared to small-cell lung cancer, cancer cells are bigger.
NSCLC types
- Adenocarcinoma: Lung outermost. The most common in non-smokers.
- Central airway squamous cell carcinoma. Strongly tied to smoking.
- Large Cell Carcinoma: Rapidly spreads and aggressively grows in any lung area.
- Rare subtypes: Adenosquamous, Sarcomatoid. Less frequent yet harder to treat.
How Serious Is NSCLC?
- Survival rates vary by stage, indicating NSCLC severity:
- Limited to the lungs 65–67%. Best prognosis: Surgery often helps.
- Regional (spread to neighbouring tissues/lymph nodes): 37-40%. Needs surgery, chemo, and radiation.
- Distance (to brain, liver, and bones): 9–12%. Most serious stage; therapy emphasizes control and quality of life.
- Total (all stages): 28–32% All-patient average.
Why NSCLC Matters
- NSCLC is the most common lung cancer, accounting for 80–85%.
- Late detection: Advanced symptoms can lead to late diagnosis.
- May spread to the brain, bones, liver, or adrenal glands, complicating treatment.
- Prognosis depends on subtype (adenocarcinoma, squamous cell, and big cell), genetic alterations, and patient health.
Severity-affecting factors
- Stage at diagnosis—early detection boosts survival.
- Age and health—healthier patients tolerate intensive therapies better.
- Some genetic alterations and subtypes react well to targeted therapy.
- Advances in immunotherapy and precision medicine improve results.
What distinguishes non-small cell lung cancer from lung cancer?
- NSCLC is a subtype of lung cancer.
- Doctors refer to “lung cancer” as a whole, whether it is NSCLC, SCLC, or rarer kinds.
- NSCLC cells are bigger and grow/spread more slowly.
- SCLC cells are tiny, divide quickly, and disseminate early.
- NSCLC can be treated with surgery, targeted therapy, immunotherapy, radiation, or chemotherapy.
- Since SCLC spreads too quickly for surgery, chemotherapy and radiation are usually used.
- Prognosis: Early detection improves the outlook for NSCLC.
- More aggressive SCLC has worse survival rates.
Why non-small cell lung cancer?
The Name Reason
- Characteristics of NSCLC cells include a greater size and increased cytoplasm around the nucleus.
- SCLC cells cluster and are smaller and rounder.
Growth Behavior:
- NSCLC grows and spreads slowly.
- SCLC spreads swiftly and aggressively.
Doctors divide lung tumors into two types based on cell size and growth pattern, which affect treatment and prognosis.
Why It Matters
- The difference affects therapy, not simply looks.
- Patients with NSCLC may benefit from surgery, targeted therapy, and immunotherapy, but SCLC requires chemotherapy and radiation due to its rapid spread.
- Survival rates varied greatly between the two categories, making categorization crucial for patient management.
What are early NSCLC symptoms?
Early NSCLC symptoms are often vague and misinterpreted as respiratory difficulties. The most common early symptoms include a persistent cough, chest pain, shortness of breath, unexplained weight loss, and fatigue. These symptoms must be detected quickly because NSCLC is more curable at this stage.
Common NSCLC Early Symptoms
- Chronic cough (greater than 8 weeks, often worsening)
- Painful chest (particularly when inhaling deeply, coughing, or laughing)
- Shortness of breath throughout daily tasks
- Unexpected weight loss without diet or activity
- Remaining fatigue or weakness after rest
- Hoarseness or voice changes over 2 weeks
- Bronchitis and pneumonia that keep coming back
- Even modest amounts of blood in the throat
Why Symptoms Are Commonly Missed
- NSCLC grows more slowly than small-cell lung cancer but can spread before symptoms appear.
- Early symptoms resemble smoking-related illnesses like chronic bronchitis or COPD or environmental chemicals like dust.
Risks that raise concerns
- Cigarette, bidi, cigar, and pipe smoking history
- The secondhand smoke
- Environmental hazards: asbestos, radon, industrial dust, heavy pollution
- Lung cancer family history
- A history of chest radiation
When to Seek Medical Help
- A persistent cough
- Breathing issues or wheezing
- Unexpected weight loss or appetite loss
- Repeated chest infections
- Sputum blood
For diagnosis, doctors may recommend chest X-rays, CT scans, or bronchoscopy.
How NSCLC Spreads
Growth Rate: NSCLC cells multiply more slowly and are bigger.
Despite slowing growth, NSCLC typically spreads silently before discovery.
Common Spreading Sites:
- Adrenal glands
- Bones
- Brain
- Liver
- Other lungs, lymph nodes
Treatable non-small cell lung cancer?
NSCLC is curable if caught early. Surgery, radiation, chemotherapy, targeted therapy, and immunotherapy are alternatives. The option is determined by the stage of cancer, the patient's health, and the genetic makeup of the tumor.
Diagnosis
- Chest X-ray, CT, PET, MRI
- Cancer cell confirmation: Bronchoscopy or needle biopsy.
- Staging tests: Assess cancer spread.
NSCLC treatment options
1. Early surgery is best
- Stage 0–II: Surgery frequently removes the tumor completely.
- Lobectomy, segmentectomy/wedge resection, and pneumonectomy are procedures.
- To prevent recurrence, adjuvant therapy (chemo, targeted medicines, immunotherapy) may be used.
2. Radiotherapy
- When surgery isn't possible or with additional therapies.
- SBRT is precise and effective at treating tiny cancers.
- Advanced symptoms can be relieved.
3. Chemotherapy
- Standard stage II–IV NSCLC treatment.
- Often with immunotherapy or chemoradiation.
- Reduces tumours before surgery or prevents recurrence after surgery.
4. Targeted Therapy
- Works against EGFR, ALK, ROS1, and KRAS- and BRAF-mutated cancers.
- Common drugs include osimertinib, alectinib, and crizotinib.
- More effective and safer than standard chemotherapy for mutation carriers.
5. Immunotherapy
- Anti-cancer immune system boost.
- Pembrolizumab, nivolumab, atezolizumab, and durvalumab are popular.
- These treatments are highly effective in advanced NSCLC patients with strong PD-L1 protein expression.
6. Hospice Care
- Advanced NSCLC treatments target pain and respiratory issues.
- Laser therapy, stents, cryotherapy, and lung drainage are options.
Ability to treat by stage: Common Treatment Results
- Stage 0: Surgery + Adjuvant Therapy Usually treatable
- In Stage II, surgery and chemotherapy/immunotherapy offer a good possibility of long-term survival.
- Stage III: Combination of chemotherapy, radiation, surgery, and immunotherapy. Treatable but difficult to cure
- Stage IV: Immunotherapy, chemo, targeted therapy, and palliative care treatment can extend life and improve quality, but not cure.
Non-small cell lung cancer causes
When normal lung cells expand uncontrollably due to genetic abnormalities, NSCLC occurs. Smoking is the main culprit, but asbestos, radon, air pollution, family history, and genetic mutations also contribute.
The main causes and risk factors of NSCLC
- Smoking (Main Cause)
- The most significant risks include cigarette, bidi, cigar, and pipe smoking.
- Tobacco smoke damages lung DNA with carcinogens.
- Smoking length and intensity increase the risk.
2. Secondhand smoke
- Nonsmokers exposed to home or workplace smoke are at risk.
3. Environmental/Occupational Exposures
- Indoor radon gas: A naturally occurring radioactive gas.
- A common construction and shipbuilding material is asbestos.
- Diesel exhaust, chromium, nickel, and arsenic dusts.
- Air pollution: Important in Chennai, where smog and industrial emissions are high.
4. Genetic factors
- NSCLC can result from EGFR, ALK, KRAS, ROS1, and BRAF mutations.
- Some mutations are more common among women and nonsmokers.
- Family history of lung cancer raises risk.
5. Prior Lung Conditions
- COPD and pulmonary fibrosis increase risk.
6. Radioactive exposure
- Risk increases with prior chest radiation therapy for breast cancer.
Prognosis
- Early-stage NSCLC: ~65% 5-year survival.
- Regional spread (nearby tissues/lymph nodes): ~37%
- The survival rate for metastatic NSCLC (spread to distant organs) is approximately 9%, depending on stage, subtype, and overall health.
Conclusion
Most lung cancer instances are non-small cell lung cancer (80–85%). It's named for its larger cancer cells than small cell lung cancer. Despite growing and spreading more slowly than small-cell lung cancer, NSCLC is nevertheless a severe disease because it typically goes undiagnosed until it is advanced.
Early detection of NSCLC can potentially cure it. Regular screening and risk factor awareness are crucial because late detection is the main obstacle. Even in advanced cases, targeted immunotherapy is improving results.







